Free Shipping on orders over $99

Bladder Pain Syndrome (Interstitial Cystitis): Understanding and treating

Pain, General, Women's Health | July 23, 2014 | Author: The Super Pharmacist

Pain, women's health

Bladder Pain Syndrome (Interstitial Cystitis): Understanding and treating

Bladder pain syndrome, or interstitial cystitis (BPS/IC), is a condition characterised by pain and/or other abnormalities in the course of bladder function, i.e. urination. The symptoms may be variable between patients, and may vary for an individual patient over time. These may include:

  • Pain in the bladder area, with or without radiation outward into the rest of the pelvic region
  • Urinary urgency (i.e. extreme pressure or drive to urinate)
  • Urinary frequency
  • Pain before urinating
  • Urinary hesitancy (i.e. difficulty initiating a stream of urine)
  • Nocturia, i.e. sleep interruptions caused by the need to urinate
  • Pain during sexual intercourse

BPS/IC is often considered a chronic illness, and can be recurrent, i.e. the symptoms may recede and then return in 'waves'. The condition is associated with a significant decrease in the quality of life of the individuals affected. Women are approximately ten times more likely to develop this condition, which affects people of all ages and socioeconomic groups.

What Causes Bladder pain syndrome, or interstitial cystitis?

Bladder pain syndrome, or interstitial cystitis is diagnosed when all other common explanations for bladder pain and dysfunction have been ruled out; in other words, it is an exclusion diagnosis.

Therefore, BPS/IC may be a syndrome caused by a combination of factors - or by a single factor that has somehow eluded scientific detection to this day.

BPS/IC is not strongly associated with microbial infection, although patients may have had a history of urinary tract infection. However, symptom 'waves' are not associated with the presence of bacteria.

Other criteria for BPS/IC include a positive response to a diagnostic bladder distention (see below). Essentially, the precise cause of this condition is not currently defined or understood. There are a number of prominent theories under investigation by the research community that may explain the illness.

These include:

Hyper-reactive Bladder

This theory is based on observations of an overlap of symptoms between BPS/IC and other similar conditions that involve abnormally frequent bladder function, e.g. overactive bladder syndrome (OAB).

Therefore, the condition may be based on abnormalities in the neurological regulation of this organ.

This is supported by the presence of increased nerve growth factor (NGF) - an important protein with a central role in the regulation of neural activity - in the urine of BPS/IC patients, and a possible link between this and the intensity of pain symptoms.

In addition, nerve damage and other types of neurological dysfunction are associated with BPS/IC.

Bladder Lining Damage/Dysfunction

A number of cell layers make up the surface of the bladder. Damage to the innermost layers of these - known as the bladder lining - is strongly associated with BPS/IC (this is the basis of the term 'interstitial cystitis'). Again, the cause of this has not been conclusively defined. Some researchers conclude that the damaged tissue may then come into contact with certain chemicals found in urine, which results in irritation, thus explaining BPS/IC symptoms. This damage may be associated with ulceration of the lining but again it is not clear whether this is a cause or a symptom of BPS/IC.

Autoimmune Component

An increasing body of evidence supports the theory of BPS/IC as an autoimmune disorder. This is a condition in which the immune system of the body attacks its own tissues, causing damage and disease. Mast cells, an immune cell type that releases histamine to destroy its targets, have been detected in the course of attacking bladder lining cells in samples taken from patients.

Psychological Component

BPS/IC is also commonly associated with psychiatric or psychological conditions, such as stress, anxiety and depression. Therefore, the condition may be comorbid with, or a symptom of, some similar mental health disorders. On the other hand, life quality impairments may be associated with depressive symptoms (such as the tendency to react to pain with disproportionate negativity) - i.e. the presence of a psychological disorder may simply influence the effects of BPS/IC.

Genetic Factors

There is some evidence that BPS/IC may be associated with specific mutations or changes in certain genes. 

In addition, BPS/IC accompanied with anxiety disorders may be associated with other specific genetic factors. 

In addition, certain foods or beverages have been identified as probable risk factors for BPS/IC development or persistence.

Possible risk factors

  • Beverages containing caffeine, e.g. coffee, tea
  • Carbonated beverages
  • Alcoholic beverages
  • Citrus fruits
  • Artificial sweeteners
  • Chili peppers

As there is no consistent aetiology of BPS/IC, treatment is mainly based on interventions that are associated with the management of symptoms.

Treatment Options

There are many treatments available for BPS/IC, which are recommended systematically based on the severity and persistence of an individual patient's symptoms. These include:

Patient Education. The education of patients about their BPS/IC, the most probable risk factors and how to avoid them, has been shown to be beneficial and to improve life quality in many cases. Patient education is often recommended in conjunction with behavioural modifications.

Behavioural Modifications. These are a range of lifestyle changes a patient may make in order to combat their symptoms. They may include avoiding dietary triggers, anxiety or stress. These are also associated with successful reduction of BPS/IC symptoms, and the concomitant effects on life quality.

Physical Therapy. This may include massage or manipulation therapy of the bladder or pelvic region. This can significantly improve BPS/IC symptoms by regulating pain, urinary frequency and/or urinary urgency.

Pharmacotherapy. These are drug therapies associated with the effective treatment of BPS/IC symptoms.

PharmacotherapyPharmacotherapy options include:

  • Amytriptiline
  • Pentosan polysulphate sodium,
  • Hydroxyzine
  • Cyclosporine A (via injection into the bladder (or intravesical injection), which inhibits abnormal function)
  • Botulinum toxin-A (i.e. Botox), which is currently under investigation as another intravesical application
  • Triamclinone injections
  • Dimethyl sulphoxide (DMSO), via instillation (i.e. A type of injection into the bladder so that the drug coats the inner lining of the organ)

Neurological Interventions. Some treatments are based on the stimulation or modulation of affected nerves, to disrupt or modify signals they transmit to the brain, which processes and perceives these as pain. Electrical nerve stimulation has been applied to BPS/IC treatment (i.e. to important nerves in the region that control bladder function and/or pain perception, e.g. the sacral nerve) with promising results. In addition, sacral neuromodulation (devices surgically implanted in the body, which emit consistent electrical modulation to a nerve) has demonstrated significant reductions in symptoms, and improvements in quality of life for BPS/IC patients. There are several advantages to neuromodulation, such as the fact that it is minimally invasive and demonstrates long-term success. Therefore, it may be a viable treatment option for patients with recurrent symptoms who have not responded to the conventional treatments mentioned above.

Bladder Distention. This is an artificially-induced increase of bladder capacity, usually done under general anaesthesia. Bladder distention is associated with medium-term pain relief in BPS/IC patients, although it is not clear how the procedure treats the condition. It is possible that distention somehow alleviates pressure or damage to nerves in the area.

Surgery. Bladder surgery is usually the last line of treatment for patients with very severe, intransigent symptoms. This may take the form of surgical denervation (i.e. to permanently inhibit pain or urinary urgency), bladder reconstruction, or urinary diversion (in which case the bladder may be removed). Reconstruction is achieved using tissue from the gastrointestinal tract. Surgery may reduce pain and urgency significantly, and also increase bladder capacity. Australia's best online pharmacy


Offiah I, McMahon SB, O'Reilly BA. Interstitial cystitis/bladder pain syndrome: diagnosis and management. International urogynecology journal.2013;24(8):1243-1256.

Quillin RB, Erickson DR. Management of interstitial cystitis/bladder pain syndrome: a urology perspective. The Urologic clinics of North America.2012;39(3):389-396.

Hsieh CH, Chang WC, Huang MC, Su TH, Li YT, Chiang HS. Treatment of interstitial cystitis in women. Taiwanese journal of obstetrics & gynecology.2012;51(4):526-532.

Lai HH, Vetter J, Jain S, Gereau RWt, Andriole GL. The overlap and distinction of self-reported symptoms between interstitial cystitis/bladder pain syndrome and overactive bladder: a questionnaire-based analysis. The Journal of urology.2014.

Bosch PC, Bosch DC. Treating interstitial cystitis/bladder pain syndrome as a chronic disease. Reviews in urology.2014;16(2):83-87.

Suskind AM, Berry SH, Suttorp MJ, Elliott MN, Clemens JQ. Symptom persistence in a community cohort of women with interstitial cystitis/bladder pain syndrome (IC/BPS): 3-, 6-, 9-, and 12-month follow-up from the RICE cohort. International urogynecology journal.2014.

Lee MH, Wu HC, Lin JY, Tan TH, Chan PC, Chen YF. Development and evaluation of an E-health system to care for patients with bladder pain syndrome/interstitial cystitis. International journal of urology : official journal of the Japanese Urological Association.2014;21 Suppl 1:62-68.

Davis NF, Brady CM, Creagh T. Interstitial cystitis/painful bladder syndrome: epidemiology, pathophysiology and evidence-based treatment options. European journal of obstetrics, gynecology, and reproductive biology.2014;175:30-37.

Vij M, Srikrishna S, Cardozo L. Interstitial cystitis: diagnosis and management. European journal of obstetrics, gynecology, and reproductive biology.2012;161(1):1-7.

Stanford E, McMurphy C. There is a low incidence of recurrent bacteriuria in painful bladder syndrome/interstitial cystitis patients followed longitudinally. International urogynecology journal and pelvic floor dysfunction.2007;18(5):551-554.

Nickel JC, Shoskes DA, Irvine-Bird K. Prevalence and impact of bacteriuria and/or urinary tract infection in interstitial cystitis/painful bladder syndrome. Urology.2010;76(4):799-803.

Dell JR, Mokrzycki ML, Jayne CJ. Differentiating interstitial cystitis from similar conditions commonly seen in gynecologic practice. European journal of obstetrics, gynecology, and reproductive biology.2009;144(2):105-109.

Kim SW, Im YJ, Choi HC, Kang HJ, Kim JY, Kim JH. Urinary nerve growth factor correlates with the severity of urgency and pain. International urogynecology journal.2014.

Cory L, Harvie HS, Northington G, Malykhina A, Whitmore K, Arya L. Association of neuropathic pain with bladder, bowel and catastrophizing symptoms in women with bladder pain syndrome. The Journal of urology.2012;187(2):503-507.

Kilpatrick LA, Ornitz E, Ibrahimovic H, et al. Gating of sensory information differs in patients with interstitial cystitis/painful bladder syndrome. The Journal of urology.2010;184(3):958-963.

Kilpatrick LA, Kutch JJ, Tillisch K, et al. Alterations in Resting State Oscillations and Connectivity in Sensory and Motor Networks in Women with Interstitial Cystitis/Painful Bladder Syndrome. The Journal of urology.2014.

Yin Z, Yang J. [Bladder interstitial cells and pathophysiology]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences.2014;39(6):644-648.

Birder LA. Urinary bladder, cystitis and nerve/urothelial interactions. Autonomic neuroscience : basic & clinical.2014;182:89-94.

Keay SK, Szekely Z, Conrads TP, et al. An antiproliferative factor from interstitial cystitis patients is a frizzled 8 protein-related sialoglycopeptide. Proceedings of the National Academy of Sciences of the United States of America.2004;101(32):11803-11808.

Fiander N. Painful bladder syndrome and interstitial cystitis: treatment options. British journal of nursing (Mark Allen Publishing).2013;22(9):S26, s28-33.

Logadottir Y, Delbro D, Lindholm C, Fall M, Peeker R. Inflammation characteristics in bladder pain syndrome ESSIC type 3C/classic interstitial cystitis. International journal of urology : official journal of the Japanese Urological Association.2014;21 Suppl 1:75-78.

Izgi K, Altuntas CZ, Bicer F, et al. Uroplakin peptide-specific autoimmunity initiates interstitial cystitis/painful bladder syndrome in mice. PloS one.2013;8(8):e72067.

Crumley S, Ge Y, Zhou H, Shen SS, Ro JY. Interstitial cystitis: another IgG4-related inflammatory disease? Annals of diagnostic pathology.2013;17(5):403-407.

Anand P, Singh B, Jaggi AS, Singh N. Mast cells: an expanding pathophysiological role from allergy to other disorders. Naunyn-Schmiedeberg's archives of pharmacology.2012;385(7):657-670.

Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology.2001;57(6 Suppl 1):47-55.

Clemens JQ, Elliott MN, Suttorp M, Berry SH. Temporal ordering of interstitial cystitis/bladder pain syndrome and non-bladder conditions. Urology.2012;80(6):1227-1231.

Chung KH, Liu SP, Lin HC, Chung SD. Bladder pain syndrome/interstitial cystitis is associated with anxiety disorder. Neurourology and urodynamics.2014;33(1):101-105.

Watkins KE, Eberhart N, Hilton L, et al. Depressive disorders and panic attacks in women with bladder pain syndrome/interstitial cystitis: a population-based sample. General hospital psychiatry.2011;33(2):143-149.

Katz L, Tripp DA, Nickel JC, Mayer R, Reimann M, van Ophoven A. Disability in women suffering from interstitial cystitis/bladder pain syndrome. BJU international.2013;111(1):114-121.

Subaran RL, Talati A, Hamilton SP, et al. A survey of putative anxiety-associated genes in panic disorder patients with and without bladder symptoms. Psychiatric genetics.2012;22(6):271-278.

Shorter B, Lesser M, Moldwin RM, Kushner L. Effect of comestibles on symptoms of interstitial cystitis. The Journal of urology.2007;178(1):145-152.

Shorter B, Ackerman M, Varvara M, Moldwin RM. Statistical Validation of the Shorter-Moldwin Food Sensitivity Questionnaire for Patients with Interstitial Cystitis/Bladder Pain Syndrome. The Journal of urology.2013.

Kuo HC, Chuang YC, Chancellor MB. Neurourology, diet, and painful bladder: highlights of the 37th annual conference of the international continence society, august 20-24, 2007, rotterdam, Netherlands. Reviews in urology.2008;10(1):70-72.

Subaran RL, Talati A, Hamilton SP, et al. A survey of putative anxiety-associated genes in panic disorder patients with and without bladder symptoms. Psychiatric genetics.2012;22(6):271-278.

FitzGerald MP, Payne CK, Lukacz ES, et al. Randomized multicenter clinical trial of myofascial physical therapy in women with interstitial cystitis/painful bladder syndrome and pelvic floor tenderness. The Journal of urology.2012;187(6):2113-2118.

O'Hare PG, 3rd, Hoffmann AR, Allen P, Gordon B, Salin L, Whitmore K. Interstitial cystitis patients' use and rating of complementary and alternative medicine therapies. International urogynecology journal.2013;24(6):977-982.

Hsieh CH, Chang WC, Huang MC, et al. Hydrodistention plus bladder training versus hydrodistention for the treatment of interstitial cystitis. Taiwanese journal of obstetrics & gynecology.2012;51(4):591-595.

Diniz S, Dinis P, Cruz F, Pinto R. Bladder pain syndrome/interstitial cystitis: present and future treatment perspectives. Minerva urologica e nefrologica = The Italian journal of urology and nephrology.2013;65(4):263-276.

Dellis A, Papatsoris AG. Intravesical treatment of bladder pain syndrome/interstitial cystitis: from the conventional regimens to the novel botulinum toxin injections. Expert opinion on investigational drugs.2014;23(6):751-757.

Tirlapur SA, Vlismas A, Ball E, Khan KS. Nerve stimulation for chronic pelvic pain and bladder pain syndrome: a systematic review. Acta obstetricia et gynecologica Scandinavica.2013;92(8):881-887.

Thompson JH, Sutherland SE, Siegel SW. Sacral neuromodulation: Therapy evolution. Indian journal of urology : IJU : journal of the Urological Society of India.2010;26(3):379-384.

Gajewski JB, Al-Zahrani AA. The long-term efficacy of sacral neuromodulation in the management of intractable cases of bladder pain syndrome: 14 years of experience in one centre. BJU international.2011;107(8):1258-1264.

Peters KM, Kandagatla P, Killinger KA, Wolfert C, Boura JA. Clinical outcomes of sacral neuromodulation in patients with neurologic conditions. Urology.2013;81(4):738-743.

Ghazwani YQ, Elkelini MS, Hassouna MM. Efficacy of sacral neuromodulation in treatment of bladder pain syndrome: long-term follow-up. Neurourology and urodynamics.2011;30(7):1271-1275.

Peters KM. Sacral neuromodulation is an effective treatment for interstitial cystitis/bladder pain syndrome: pro. The Journal of urology.2012;188(6):2043-2044.

Grover S, Srivastava A, Lee R, Tewari AK, Te AE. Role of inflammation in bladder function and interstitial cystitis. Therapeutic advances in urology.2011;3(1):19-33.

Bondavalli C, Schiavon L, Dall'Oglio B, et al. [Interstitial cystitis: surgical treatment]. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica / Associazione ricerche in urologia.1999;71(5):327-332.

van Ophoven A, Oberpenning F. [Open surgical therapy of interstitial cystitis]. Der Urologe. Ausg. A.2000;39(6):547-550.

Kim HJ, Lee JS, Cho WJ, et al. Efficacy and safety of augmentation ileocystoplasty combined with supratrigonal cystectomy for the treatment of refractory bladder pain syndrome/interstitial cystitis with Hunner's lesion. International journal of urology : official journal of the Japanese Urological Association.2014;21 Suppl 1:69-73.

backBack to Blog Home